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Summary 
Lymphocytes of melanoma patients can be restimulated in vitro with autologous tumor cells 
to generate antitumor cytolytic T lymphocytes (CTL). Previous reports have indicated that, when 
such CTL are obtained from HLA-A2 melanoma patients, they often display broad reactivity 
on A2 melanoma cell lines. Such antitumor CTL clones, which appeared to recognize the same 
antigen, were isolated from two patients. We report here the cloning of a cDNA that directs 
the expression of the antigen recognized by these CTL. This cDNA corresponds to the transcript 
of the tyrosinase gene. The gene was found to be active in all tested melanoma samples and 
in most melanoma cell lines. Among normal cells, only melanocytes appear to express the gene. 
The tyrosinase antigen presented by HLA-A2 may therefore constitute a useful target for specific 
immunotherapy of melanoma. But possible adverse effects of antityrosinase immunization, such 
as the destruction of normal melanocytes and its consequences, will have to be examined before 
clinical pilot studies can be undertaken. 
W 
hen blood lymphocytes of melanoma patients are 
stimulated in vitro with tumor cells of the same pa- 
tient, one often observes the proliferation of T lymphocytes 
that exert cytolytic activity on the autologous melanoma cells 
(1-3).  From these responder cell populations, it is often pos- 
sible to isolate by limiting dilution cytolytic T lymphocyte 
(CTL)  1 dones that display a high activity on the tumor cells 
and do not lyse autologous EBV-transformed lymphoblastoid 
cell lines, fibroblasts, or NK targets such as K562 (3-6). With 
such antitumor CTL clones it is possible to select in vitro 
antigen-loss tumor cell variants. This approach indicated that 
melanoma cell lines display several different antigens recog- 
nized by autologous CTL (7,  8). 
By transfecting into an antigen-loss variant a cosmid li- 
brary prepared with the DNA of melanoma cell line MZ2- 
MEL, we obtained transfectants that expressed an antigen 
recognized by an autologous CTL clone (9). This led to the 
identification of gene MAGE-1, which directs the expression 
of antigen MZ2-E (10). Gene MAGE-1 is expressed in '~40% 
of melanoma tumor samples.  It is also expressed on some 
other tumor types, such as lung and breast carcinoma (11). 
1 Abbreviation used in this paper: CTL, cytolytic T lymphocyte. 
No expression was found in a large panel of normal tissues, 
with the exception of testis (F. Brasseur, unpublished results). 
Antigen MZ2-E is presented by class I MHC molecule HLA- 
A1.  The  MAGE-l-encoded  antigenic  peptide  has  been 
identified as a nonapeptide (12). Melanoma cells of other 
HLA-A1 patients that express gene MAGE-1 are recognized 
by the anti-MZ2-E CTL of the original patient. 
Because MAGE-1 is not expressed in most normal tissues, 
antigen MZ2-E may constitute a useful target for specific im- 
munotherapy. But only 10% of melanoma patients express 
this antigen on their tumor, since this requires that they carry 
the HLA-A1 allele (as do 26% of caucasians) and that their 
tumor expresses MAGE-1  (as do 40% of melanomas). It is 
therefore important to identify additional genes that code 
for tumor rejection antigens. Those that direct the expres- 
sion of antigens presented by HLA-A2 should be particu- 
larly useful since this allele is very frequent (49% of caucasians). 
Several groups have derived from HLA-A2 patients CTL 
that lyse not only the autologous tumor cells but also a large 
proportion of the cell lines derived from the tumors of other 
HLA-A2 patients (13, 14). We have isolated such CTL clones 
from two melanoma patients, and we report here the identi- 
fication of the gene that codes for their target antigen. 
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Patients and Cell Lines.  In 1987, patient LB24 developed a malig- 
nant melanoma on the lower left leg cured by a large excision. She 
relapsed in 1988 with three metastatic skin nodules above and below 
the primary location. A half-calf amputation was performed. The 
patient is presently disease free. Tumor cell line LB24-MEL was 
obtained by adapting cells from the amputation sample to tissue 
culture. The melanoma cells were cultured in Iscove medium (Gibco 
Laboratories,  Grand  Island,  NY)  containing  10%  FCS,  sup- 
plemented with t-arginine (116 rag/liter), t-asparagine (36 mg/liter), 
and t-glutamine (216 rag/liter). 
Patient SK29(AV) had recurrent metastatic malignant melanoma 
from 1975 to 1978. Melanoma cell line SK-MEL,29 was initiated 
from a metastatic lesion in 1976. We will refer to it as SK29-MEL 
(this change in nomenclature enables us to identify easily all ceils 
coming from the  same patient:  SK29-MEL,  SK29-CTL  ....  ). 
SK29-MEL was a gift from Dr. Old (Memorial Sloan-Kettering 
Cancer Center, New York).  SK29-MEL was cloned by limiting 
dilution and clone SK29-MEL.1  was selected for further experi- 
ments (6). Melanoma cell line NA8-MEL was a gift from Dr. F. 
Jotereau (Inserm U211, Nantes, France).  The culture medium of 
SK29-MEL and NA8-MEL was DME (Gibco Laboratories) con- 
taining 10%  FCS (Gibco Laboratories), 10 mM Hepes, and 4.5 
g/liter glucose.  The cells were cultured at 37*C in 8% CO2. 
Derivation and Culture of CTL Clones.  Mixed lymphocyte tumor 
cultures (MLTC) of PBL and tumor cells isolated from patient LB24 
were performed as previously described (3), except that the medium 
was supplemented with 5 U/m1 of human rib4 (a gift from R. 
Devos,  Roche Research, Gent, Belgium). 
Derivation and long-term culture of CTL clones from PBL of 
patient SK29(AV) was previously described (8).  The IVSB CTL 
line was derived from a MLTC responder call population without 
cloning. However, eight subclones were isolated by limiting dilu- 
tion and they were tested on all the autologous targets described 
in Results.  All had exactly the same pattern of lysis. We therefore 
refer to this monospecific line as CTL clone IVSB. 
Assay for Cytolytic Activity.  The protocol was  previously de- 
scribed  (15). Target cells were treated for 48 h with 50 U/m1 of 
human rlFN-3, (Boehringer, Ingelheim, Germany). CTL and 1,000 
SlCr-labeled targets were incubated at various ratios in 96 conical 
microplates in a final volume of 200 ~d. Chromium release in the 
supernatant was measured after 4 h  of incubation. 
Construction of the cDNA Library.  Total RNA was isolated from 
clone SK29-MEL.1 and poly(A)  § KNA was prepared by oligo(dT) 
binding (mRNA purification kit; Pharmacia Fine Chemicals,  Pis- 
caraway, NJ). mRNA was converted to cDNA, ligated to EcoRI 
adaptors,  and inserted into the EcolLI  site  of expression vector 
pcDNAI/Amp (Invitrogen Corporation, Oxon, U.K.) as described 
in the SuperScript plasmid system kit (Gibco BKL, Gaithersburg, 
MD). Recombinant plasmids were electroporated into JM101 Esch- 
erichia coli bacteria (Genepulser; Bio-tLad Laboratories,  Richmond, 
CA) at 1 pulse at 25 t~farad and 2,500 V, that were selected with 
ampicillin  (50 tzg/ml). 
Transfection of COS-7 Cells and Screening of Transfectants.  DNA 
from pools  of bacteria was  transfected by the  DEAE-dextran- 
chloroquine method into 3  x  104 COS-7 calls (16).  100 ng of 
plasmid pcDNAI/Amp-A2 and 100 ng of DNA of a pool of the 
cDNA library were used. Plasmid pcDNAI/Amp-A2 contains the 
HLA-A2 gene isolated from a CTL done of patient SK29(AV). 
The COS cells were incubated for 48 h at 37~  The medium was 
then discarded and 1,000-2,000 CTL were added in 100/zl of Iscove 
medium containing 10% human serum. For CTL clone 210/9, the 
medium was supplemented with 25 U/ml IL-2 (a gift of Biogen, 
Geneva,  Switzerland). After 24 h, the supernatant was collected 
and its TNF content was determined by its cytolytic effect on W13 
cells as previously described (9). 
Transfection of  a Melanoma Cell Line.  Melanoma NA8-MEL line 
was transfected by the calcium phosphate precipitation method, 
as described  (9). Briefly, 7.5  x  l0  s cells were seeded in 4.5 ml of 
medium. 24 h later,  they were transfected with 2/xg of plasmid 
pSVtkneo~/(17) and 20/~g ofcDNA 123.B2. After 48 h, the cells 
were seeded in microcultures at 2,000 cells/well in 200/A of medium 
containing 2 mg/ml of neomycin analogue G418 (Gibco Laborato- 
ries).  NeoR colonies were selected for further experiments. 
PCR Assays  for Tyrosinase Expression.  Isolation of total RNA 
from tumor samples was performed as described (18). RNA from 
melanocyte culture was a gift from Dr. Old. Reverse transcription 
was performed on 2 #g of total RNA with an oligo(dT) primer. 
cDNA corresponding to 100 ng of total RNA (104 cell equiva- 
lents) was  amplified  for 35 cycles by PCR with primers.  These 
primers are located in different exons to exclude the amplification 
of genomic DNA.  An aliquot of the PCR reaction was run on 
a 1% agarose gel stained with ethidium bromide. To ensure that 
the RNA were not degraded, the cDNA products were tested for 
the presence of both human B-actin and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). 
For quantitative expression measurements, cDNA was obtained 
as above. RNA obtained from the clone SK29-MEL.1 was included 
pure and serially diluted in each series of quantitative PCR. The 
number of PCR cycles was reduced to 22 so that a linear dilution 
curve of the standard was obtained. Trace amounts of labeled dCTP 
(0.2 #Ci) were added and accurate quantitation was obtained using 
the phosphor-imaging technology (Phosphor-Imager; Molecular 
Dynamics, Sunnyvale, CA). Expression of the various samples were 
normalized for RNA integrity by taking into account the expres- 
sion level of the B-actin gene. When they showed values above that 
found with SK29-MEL RNA,  the samples were evaluated  again 
after dilution. 
Results 
An Antigen Recognized on HLA-A2 Melanoma Cells by CTL 
Clones of Two Patients.  By stimulating blood lymphocytes 
of HLA-A2 patients SK29(AV) and LB24 with irradiated cells 
of autologous melanoma lines SK29-MEL and LB24-MEL, 
respectively, responder lymphocytes were obtained that lysed 
the autologous tumor cells.  CTL clone IVSB was isolated 
from responder ceils of patient SK29(AV),  and CTL clone 
210/9 was isolated from those of patient LB24. These CTL 
clones displayed high lytic activity on the autologous tumor 
cell lines  (Fig.  1). 
Both CTL showed broad reactivity on HLA-A2 melanoma 
cells.  First,  they lysed the melanoma cell lines of both pa- 
tients. Further, they recognized most but not all melanoma 
cell lines derived from HLA-A2 patients  (Fig.  1).  Definite 
evidence that their target antigens were presented by HLA-A2 
was provided by a variant of SK29-MEL that had been selected 
in vitro for resistance to another antitumor  CTL clone of 
patient  SK29(AV).  This variant had lost  the expression of 
HLA-A2. It proved resistant to CTL clones IVSB and 210/9 
(Fig. 1). When the HLA-A2 gene was reintroduced by trans- 
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Figure  1.  Sensitivity  of melanoma target cells to lysis by CTL clones 210/9 and IVSB. Lysis of chromium-labeled cells was measured after 4 h. 
Melanoma cell lines SK29, LB24, MI3046, LB4, and MZ13 are derived from HLA-A2 patients. SK29-MEL.1.22  is a variant of SK29-MEL selected 
in vitro with an autologous CTL clone resulting in the loss of HLA-A2 (8). SK29-MEL.1.22.4 is the same variant transfected  with the HLA-A2 gene 
of patient SK29. SK29-MEL1.5.86 is an antigen-loss variant of SK29-MEL selected in vitro for resistance to CTL IVSB (30). 
fection into this variant, it regained sensitivity to both CTL 
(Fig.  1). 
Evidence that  CTL IVSB and 210/9 recognize the same 
antigen was provided by another antigen-loss variant of SK29- 
MEL. This variant, named SK29-MEL1.5.86,  had been selected 
for resistance to CTL IVSB and had kept the expression of 
HLA-A2. It also proved resistant to lysis by CTL 210/9 (Fig. 
1). The antigen, which was common to SK29-MEL and LB24- 
MEL and was recognized by autologous CTL clones IVSB 
and 210/9, was named SK29-Ab or LB24-Ab. We will refer 
to it  as Ab. 
Cloning of a cDNA Expressing Antigen At~  We set out 
to identify the gene coding for antigen Ab by transfecting 
an expression library in COS cells (16). A cDNA library was 
prepared from RNA of a clonal  subline of melanoma cell 
line SK29-MEL and it was cloned into plasmid pcDNAI/Amp. 
Bacteria were transformed with the products of ligation and 
the library was divided into 700 pools of 200 bacteria. Each 
pool contained ',~100 different cDNAs because only 50% of 
the plasmids were found to carry an insert.  Plasmid DNA 
was prepared from each pool and was then cotransfected into 
COS-7  cells  together  with  the  HLA-A2  gene  of patient 
SK29(AV) cloned into pcDNAI/Amp. After 48 h, the trans- 
fected cells were tested for expression of antigen Ab by their 
ability to cause TNF release by the relevant CTL (9). The 
amount of TNF released by the CTL was measured by the 
cytotoxic effect of the culture supernatant on Wehi-13 cells. 
Each  cDNA  pool  was  transfected  in  duplicate  COS 
microcultures. One microculture was tested with CTL 210/9 
and the other with CTL IVSB.  For the 700 microcultures 
tested with CTL IVSB, all supernatants contained between 
0.6 and 4 pg/ml of TNF, except for four that contained be- 
tween 10 and 20 pg/ml. The four duplicate cultures also dearly 
stood out among  those tested with  CTL 210/9 as having 
produced more TNF than the others. Two of the four corre- 
sponding pools of bacteria were subcloned and plasmid DNA 
was extracted from each of"~500 bacteria. The DNA of these 
plasmids was transfected into COS cells and the transfectants 
were tested for their ability to stimulate CTL 210/9 and IVSB. 
One positive cDNA clone was found in each pool. The very 
effective stimulation of CTL clone 210/9 by COS cells trans- 
fected with cDNA clone 123.B2 is displayed in Fig. 2. This 
stimulation appeared to be specific: another A2-restricted CTL 
of patient SK29(AV), which was known to recognize another 
antigen, was not stimulated by the transfected COS cells (data 
not  shown). 
To confirm the results obtained with the transient  COS 
cell transfectants, we used HLA-A2 melanoma cell line NAS- 
MEL, which was not recognized by anti-Ab CTL 210/9 or 
IVSB.  This cell was cotransfected with the pcDNAI/Amp 
construct containing cDNA 123.B2 and with a plasmid con~ 
ferring resistance to geneticin. Geneticin-resistant stable trans- 
fectant clones were isolated. 7 of 15 proved sensitive to lysis 
by CTL 210/9 and IVSB (Fig. 3). They were not lysed by 
another A2-restricted CTL directed against another antigen. 
Antigen Ab Is a Product of the Tyrosinase Gene.  cDNA 
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Figure 2.  Stimulation of CTL 210/9 by COS cells transfected with 
pcDNAI/Amp constructs containing HLA-A2 and eDNA 123.B2 as de- 
scribed in Materials  and Methods. Controls were transfected  with HLA-A2 
alone. CTL 210/9 was added and the supernatant  was tested on Wehi-13 
cells. 
123.B2 was sequenced and found to be almost identical to 
a human tyrosinase cDNA previously isolated from a mela- 
noma cell by Bouchard et al. (19).  Both cDNAs contain an 
open reading frame of ~,1,600 nucleotides that codes for the 
enzyme tyrosinase. Only three nucleotides differed between 
the two sequences, each difference resulting in an amino acid 
change.  Two of the differences were located in exon 1 and 
one in exon 4  (Fig.  4).  In  two of three positions,  our  se- 
quence was identical to another tyrosinase sequence reported 
previously (20). 
Because of our previous observations that point mutations 
occurring on tumor cells can generate new antigens recog- 
nized by autologous CTL (21, 22), we compared the sequence 
of the tyrosinase eDNA obtained from the SK29 melanoma 
cells to that of the tyrosinase gene present in other cells of 
the same patient. We applied PCK amplification to the DNA 
of a CTL clone of patient  SK29(AV) (Fig.  4). Five cloned 
Table  1.  Quantitative Measurement of the Expression of the Tyrosinase Gene 
Expression  of tyrosinase 
(percent relative  to SK29-MEL) 
Melanoma cell lines 
SK29-MEL. 1  100 
LB39-MEL  280 
NA8-MEL  7 
LB24-MEL  760 
SK23-MEL  280 





LB357  88 
LG18  63 
LB373  150 
LB239  470 
LB15  97 
LB537  170 
LB435  620 
LB224  390 
530 
Sample  1  0.1 
Sample 2  12 
Sample 3  35 
Sample 4  2 
Sample 5  25 
Naevus  170 
eDNA synthesis and 22 cycles of PCR amplification  were performed as described in Materials and Methods. Results were normalized according 
to the expression of fl-actin. The results are expressed as the percentage of the level of expression of melanoma line SK29-MEL. 
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Figure  3.  Expression of antigen Ab in HLA-A2 mela- 
noma cell line NAS-MEL transfected with cDNA 123.B2. 
The calls were cotransfected  with the pcDNAI/Amp- 
cDNA 123.B2 construct and pSVtkneo/$ as described in 
Materials  and Methods.  Geneticin-resistant  transfectant 
clone NA8.c12.4 was tested for sensitivity to lysis by anti- 
Ab CTL IVSB and 210/9. CTL 1/95 is an A2-restricted 
CTL isolated from mdanoma patient  LB39 and directed 
against  another antigen. 
Tyrosinase coding uquence 
400  800  1200  1600bp 
'  I  '  1=141  3  I 
ATC  :1  TAT:Y  CGA:R 
ATG :M  TAT:Y  CAA :Q 
ATG :M  TCT  :  S  CAA  :Q 
ATG :M  TCT  :  S  CAA:Q 
ATG :  M  TCT  :  S  CGA  :R  ] 
cDNA  of  Bouchard et el. 
cDNA  of  Kwon of cl. 
cDNA  123.92  of  melanoma  gK29-MEL 
PCR  produce-  obtained from  DNA  of SK29 CTL 
Figure  4.  Codons  and  amino 
acids at  the three  positions  (537, 
575,  1205) where the sequence of 
cDNA  123.B2 and  that  of  the 
cDNA done isolated by 8ouchard 
et  al.  (19) differ. The  cDNA of 
Kwon et al. (20) differs from both 
of these sequences at a few other po- 
sitions not shown here. The bound- 
aries  of exons  1-5  are  indicated. 
Other explanations are given in the 
text. 
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all identical to that derived from the melanoma cells. For exon 
4, we obtained two different PCR products:  one identical 
to that of cDNA 123.B2 and another identical to the sequence 
of Bouchard et al. (19). Thus, it appears that the three amino 
acid changes reflect a degree of polymorphism in the tyrosinase 
gene, and that patient SK29(AV) carries two alleles that differ 
at one position of exon 4. We conclude that the tyrosinase 
protein synthesized in the melanoma cells is identical to a 
product  present  in  the  normal  melanocytes  of  patient 
SK29(AV). 
Tyrosinase (monophenol,3,4-dihydroxyphenylalanine: ox- 
ygen oxydoreductase,  E.C.1.14.18.1),  which  catalyses  the 
synthesis of the melanin precursor dihydroxyphenylalanine 
(DOPA), has been reported to be specific for melanocytes. 
In adrenal cells and catecholinergic neurones, a similar reac- 
tion is catalyzed by tyrosine hydroxylase, an enzyme with 
an unrelated sequence (23).  We verified the pattern of ex- 
pression  of tyrosinase by  reverse  transcription  and  PCR 
amplification of RNA prepared from various cells. All of 39 
melanoma tumor samples were positive.  Among melanoma 
cell lines we found 14 positives out of 21. No expression was 
found in tissues collected from heart, liver, kidney, lung, breast, 
ovary, prostate, testis,  adrenals,  and brain (including a sub- 
stantia nigra sample). The level of expression found in mela- 
noma samples ranged from 60 to 750% of that observed with 
the SK29-MEL cell line.  A  melanocyte culture displayed a 
level of expression that was about five times higher than that 
of SK29-MEL. Skin samples varied from 0.1 to 35% of the 
level observed with SK29-MEL (Table  1). 
Discussion 
The tyrosinase gene is the third gene that we have found 
to direct the expression of an antigen recognized on tumors 
by autologous CTL. The first gene was P1A, a gene expressed 
by mouse mastocytoma P815 (24).  The second was human 
gene MAGE-1 (10). P1A and MAGE-1 have identical sequences 
in the tumor cells that express the relevant antigen and in 
autologous normal cells that do not. The presence of the an- 
tigen on the tumor cells is due to the expression of these 
genes, which are silent or nearly silent in most normal tissues. 
Presumably, this absence of expression in normal tissues allows 
for incomplete tolerance so that CTL against these antigens 
can be raised in vitro.  Our evidence indicates that antigen 
SK29-Ab is also produced by a gene, tyrosinase, which is 
identical in the melanoma cells and in the normal cells of 
patient SK29(AV). We presume that melanocytes, the normal 
cells found to express  the tyrosinase gene, also express an- 
tigen Ab, even though direct evidence is lacking. 
Contrary to the antigen encoded by P1A and MAGE-1, 
the SK29-Ab antigen should be considered as a differentia- 
tion antigen since the gene is expressed specifically in mela- 
nocytes, the normal cell type from which the tumor is de- 
rived. It appears  therefore that for differentiation antigens 
as well, tolerance is not absolute. However, it is possible that 
the high affinity lymphocytes have been eliminated by toler- 
ance, and we may find that only CTL of relatively weak affinity 
can be obtained against such antigens. The observation that 
immune responses against differentiation antigens are not en- 
tirely suppressed by tolerance have been made previously with 
antibodies (25). Watanabe et al. (26) observed that some mela- 
noma patients produced antibodies against ganglioside GD2, 
a structure that appears to be restricted to normal and malig- 
nant cells of neuroectodermal origin. Glycoprotein gp75, a 
very abundant  intracellular glycoprotein expressed in pig- 
mented human melanocytes and melanomas, was also recog- 
nized by antibodies present in the serum of a melanoma pa- 
tient (27). This protein, which is the human homologue of 
the product of the mouse b (brown) locus, is also a differen- 
tiation antigen since it is specific for the ceils of the melano- 
cytic lineage (28). 
Can a differentiation antigen like that encoded by tyrosinase 
serve as a useful target for immunotherapy? One argument 
in favor of this is provided by reports that destruction of mela- 
nocytes resulting in vitiligo is occasionally associated with 
melanoma regression and prolonged survival (29). Neverthe- 
less, because melanocytes are present in tissues other than skin, 
one possible critical location being the choroid of the eye, 
it will be important to ascertain in a mouse model that T 
lymphocytes directed against tyrosinase antigens do not have 
unacceptable adverse effects on normal tissues. 
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